CONTENT OF HEMERIN AND FEATURES OF FAT DISTRIBUTION IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY
DOI:
https://doi.org/10.32689/2663-0672-2023-4-6Keywords:
obesity, BMI, chemerin, type 2 diabetesAbstract
Ukraine ranks among the countries with a high incidence of type 2 diabetes (T2D), with 1,226,000 diagnosed cases, including approximately 190,000 insulin-dependent individuals. Notably, at the 2014 European Cardiology Congress on "Innovations and the Heart," diabetes combined with obesity was termed a lethal combination. In recent years, adipose tissue has been considered an endocrine organ producing various adipokines – biologically active molecules with both systemic and local effects. One such recently discovered adipokine is chemerin, closely associated with the development of metabolic disorders, including type 2 diabetes and obesity. The potential role of chemerin in regulating carbohydrate metabolism and insulin resistance remains controversial and insufficiently studied. Objective. The aim of our study is to investigate the serum chemerin levels in patients with type 2 diabetes, considering body mass index (BMI), degree and topography of fat tissue deposition, insulin levels, and the homeostatic model assessment of insulin resistance, HOMA index. Materials and Methods. The study involved 83 patients with type 2 diabetes and varying BMI; the average age of the group was 43±4.6 years, predominantly male (53%). A comparison group comprised 20 individuals with normal BMI. Control chemerin levels were obtained from a group of 20 practically healthy patients of similar age and gender. The diagnosis of type 2 diabetes was confirmed according to the unified protocol criteria for diabetes care (Order of the Ministry of Health of Ukraine dated 21.12.2012, No. 1118). Obesity presence and severity were assessed based on the International Diabetes Federation (IDF, 2005) criteria using the BMI calculation. Results. Chemerin levels in the serum of the control group averaged 3.89 ng/ml, while patients in the comparison group exhibited a 1.2-fold increase. Investigation of chemerin in patients with altered BMI showed an increase compared to the comparison group. Conclusions. The course of type 2 diabetes leads to an increase in chemerin synthesis (an adipose tissue cytokine), with its content having a direct correlation with BMI. Elevated chemerin levels in patients with type 2 diabetes can be utilized as a biomarker for obesity and metabolic disorders.
References
Taylor E. B. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clinical Science. 2021. Vol. 135, № 6. P. 731–752.
Babu S., Krishnan M., Chinnaiyan M. Tumor Necrosis Factor Receptors (TNFR s): a Novel Biomarker for Diabetic Kidney Disease Progression. SN Comprehensive Clinical Medicine. 2023. Vol. 5, № 1.
The association between serum adipokines levels with senile osteoporosis: a systematic review and meta-analysis / J. Wang et al. Frontiers in Endocrinology. 2023. Vol. 14.
DNA Methylation Modulates Aging Process in Adipocytes / H. Xie et al. Aging and disease. 2022. Vol. 13, no. 2. P. 433.
Weight Cycling and Knee Joint Degeneration in Individuals with Overweight or Obesity: Four‐Y ear Magnetic Resonance Imaging Data from the Osteoarthritis Initiative / G. B. Joseph et al. Obesity. 2021. Vol. 29, no. 5. P. 909–918.
Epigenetic and non-epigenetic regulation of Klotho in kidney disease / A. Kale et al. Life Sciences. 2021. Vol. 264. P. 118644.
Helfer G., Wu Q.-F. Chemerin: a multifaceted adipokine involved in metabolic disorders. Journal of Endocrinology. 2018. Vol. 238, no. 2. P. R79–R94.
Chemerin–A new adipokine that modulates adipogenesis via its own receptor / S.-g. Roh et al. Biochemical and Biophysical Research Communications. 2007. Vol. 362, no. 4. P. 1013–1018.
Fischer T. F., Beck-Sickinger A. G. Chemerin – exploring a versatile adipokine. Biological Chemistry. 2022.
Chemerin Isoforms and Activity in Obesity / C. Buechler et al. International Journal of Molecular Sciences. 2019. Vol. 20, no. 5. P. 1128.
The role of Chemerin in human diseases / G. Yue et al. Cytokine. 2023. Vol. 162. P. 156089.
Balaban Y. Irisin and Chemerin Levels in Patients with Type 2 Diabetes Mellitus. Acta Endocrinologica (Bucharest). 2019. Vol. 15, no. 4. P. 442–446.
Chemerin/CM KLR 1 Axis Promotes Inflammation and Pyroptosis by Activating NLRP 3 Inflammasome in Diabetic Cardiomyopathy Rat / Y. Xie et al. Frontiers in Physiology. 2020. Vol. 11.
The adipokine chemerin augments vascular reactivity to contractile stimuli via activation of the ME K-ER K1/2 pathway / N. S. Lobato et al. Life Sciences. 2012. Vol. 91, no. 13-14. P. 600–606.
Rourke J. L., Dranse H. J., Sinal C. J. Towards an integrative approach to understanding the role of chemerin in human health and disease. Obesity Reviews. 2012. Vol. 14, no. 3. P. 245–262.
